• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by MorphoSys AG

    8/5/24 8:14:34 AM ET
    $MOR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MOR alert in real time by email
    6-K 1 a240805_6kxcoverpage.htm 6-K Document

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    FORM 6-K
     
    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
    UNDER THE SECURITIES EXCHANGE ACT OF 1934
     
    For the month of August 2024
     
    COMMISSION FILE NUMBER 001-38455
     
    MorphoSys AG
     
    Semmelweisstrasse 7
    82152 Planegg
    Germany
    (Address of principal executive offices)
     
    Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F: Form 20-F x Form 40-F ¨







    On August 5, 2024, MorphoSys AG (the “Company”) published a press release announcing that it has completed the voluntary delisting of its shares from the Frankfurt Stock Exchange and its American Depositary Shares (“ADSs”) from the Nasdaq Global Market (“Nasdaq”), attached hereto as Exhibit 99.1.





    Exhibits

    99.1    MorphoSys Completes Voluntary Delisting from the Frankfurt Stock Exchange and Nasdaq Global Market








    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

        MORPHOSYS AG (Registrant)

    Date: August 5, 2024         
        By:    /s/ i.A. Isabelle Degbegni
            Name: Isabelle Degbegni
            Title:    Director Investor Relations
        

        By:    /s/ i.A. Dr. Robert Mayer    
            Name: Dr. Robert Mayer
            Title:    Director Investor Relations


    Get the next $MOR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MOR

    DatePrice TargetRatingAnalyst
    3/14/2024Overweight → Equal Weight
    Wells Fargo
    1/16/2024$9.19 → $10.40Overweight → Equal-Weight
    Morgan Stanley
    10/13/2023$3.70 → $9.19Underweight → Overweight
    Morgan Stanley
    9/15/2023$3.50 → $9.25Sell → Neutral
    Goldman
    7/17/2023Sell → Hold
    Deutsche Bank
    6/16/2023$3.30 → $10.00Underweight → Overweight
    JP Morgan
    6/16/2023$17.00Overweight
    Wells Fargo
    5/31/2023Buy
    UBS
    More analyst ratings